Skip to main
MNKD

MannKind (MNKD) Stock Forecast & Price Target

MannKind (MNKD) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 57%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

MannKind is expected to see significant revenue growth in the upcoming years, with potential new drug approvals and partnerships presenting major catalysts. Although there are risks associated with commercial execution, clinical trials, and regulations, as well as the potential for a partner to control commercialization of key assets, the company's strong product portfolio and potential for growth make it a compelling investment opportunity. Additionally, upcoming catalysts such as the FUROSCIX ReadyFlow autoinjector PDUFA and TETON-1 study have the potential to significantly increase the company's cash flow and addressable market, making it a high-risk, high-reward investment opportunity.

Bears say

MannKind is facing short-term challenges with lower revenue and earnings reported for 1Q26, but their long-term potential lies in the revenue streams from their partnership with United Therapeutics for Tyvaso DPI, which has yet to be fully appreciated by the market. With multiple upcoming catalysts and a strong balance sheet, there is a favorable risk-reward for MNKD shares despite their challenges in the near-term.

MannKind (MNKD) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 57% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MannKind (MNKD) Forecast

Analysts have given MannKind (MNKD) a Buy based on their latest research and market trends.

According to 7 analysts, MannKind (MNKD) has a Buy consensus rating as of Jul 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MannKind (MNKD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.